Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Emergent BioSolutions Inc EBS

Healthcare Biotechnology
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial... see more

Recent & Breaking News (NYSE:EBS)

Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2014

Business Wire August 7, 2014

Emergent BioSolutions Submits Biologics License Application to FDA for Anthrax Immune Globulin Intravenous (Human)

Business Wire August 7, 2014

Emergent BioSolutions to Release Second Quarter 2014 Financial Results and Conduct a Conference Call on August 7, 2014

Business Wire July 10, 2014

Emergent BioSolutions to Participate in June 2014 Investor Conferences

Business Wire May 29, 2014

Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 22, 2014 at 9:00 AM Eastern; Webcast Will Be Available

Business Wire May 15, 2014

Emergent BioSolutions Reports First Quarter 2014 Financial Results

Business Wire May 8, 2014

Emergent BioSolutions to Release First Quarter 2014 Financial Results and Conduct a Conference Call on May 8, 2014

Business Wire April 23, 2014

Emergent BioSolutions and FDA Finalize Comparability Protocols Enabling Manufacturing of BioThrax Consistency Lots in Building 55

Business Wire April 22, 2014

Emergent BioSolutions Receives Orphan Drug Designation for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease

Business Wire April 21, 2014

Pharma-Bio 2Q14 Update: $9 Billion in Project Starts Reflects 91% Gain in Industry Capital Investment, an Industrial Info News Alert

Marketwired April 18, 2014

Pharma-Bio 2Q14 Update: $9 Billion in Project Starts Reflects 91% Gain in Industry Capital Investment, an Industrial Info News Alert

Marketwired April 18, 2014

Emergent BioSolutions to Participate in May 2014 Investor Conferences

Business Wire April 17, 2014

Emergent BioSolutions Successfully Completes Pivotal Clinical Study to Support Expanded Indication for BioThrax

Business Wire April 16, 2014

Emergent BioSolutions Reports Financial Results for 2013

Business Wire March 6, 2014

Emergent BioSolutions to Release Fourth Quarter and Full Year 2013 Financial Results and Conduct a Conference Call on March 6, 2014

Business Wire March 3, 2014

Baltimore Attracts $5.6 Billion in Construction Activity, an Industrial Info News Alert

Marketwired February 27, 2014

Emergent BioSolutions Completes Acquisition of Cangene Corporation

Business Wire February 21, 2014

Emergent BioSolutions to Webcast Presentations at February and March 2014 Investor Conferences

Business Wire February 3, 2014

Emergent BioSolutions Announces Completion of $250 Million Convertible Senior Notes Offering

Business Wire January 29, 2014

Emergent BioSolutions Announces Expiration of the Hart-Scott-Rodino Waiting Period for Emergent's Acquisition of Cangene Corporation

Business Wire January 28, 2014